What is the 13F Pro Quality Score for AIM?

13F Pro ranks AIM ImmunoTech Inc. (AIM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AIM's current score at https://13fpro.ai/research/AIM (free sign-up required for the full ranking).

Which hedge funds own the most AIM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AIM include GEODE CAPITAL MANAGEMENT,, XTX Topco Ltd, JANE STREET GROUP,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AIM as soon as new 13F filings post.

Where does 13F Pro source AIM data?

All AIM ImmunoTech Inc. fundamentals and ownership data come directly from SEC EDGAR. AIM ImmunoTech Inc. files with the SEC under CIK 946644. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AIM in?

AIM ImmunoTech Inc. (AIM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AIM research updated on 13F Pro?

AIM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AIM ImmunoTech Inc.(AIM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 946644 AIM stock profile & AI dashboard →

13F Pro Quality Score

8.9/100

Rank #2,824 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

5.7/100

Profitability

0.5/100

Balance Sheet

30.0/100

Earnings Quality

30.0/100

Free Cash Flow

0.4/100

Institutional Flow

27.9/100

Revenue Scale

0.1/100

Dilution Risk

4.0/100

AIM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AIM ImmunoTech Inc. (AIM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AIM at 8.9/100 on a 32-signal composite quality model, placing it at rank #2,824 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.1) and free cash flow (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AIM ImmunoTech Inc. reports quarterly revenue of $22.0K, net income of $-3.0M, free cash flow of $-2.7M. Top institutional holders of AIM by reported 13-F value include GEODE CAPITAL MANAGEMENT,, XTX Topco Ltd, JANE STREET GROUP,, based on the most recent SEC filings. AIM trades on the NYSE exchange and files with the SEC under CIK 946644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AIM ImmunoTech Inc. directly from SEC EDGAR.

✦

Fun facts about AIM ImmunoTech Inc.

Quirks, history, and lore behind AIM — the kind of stuff that makes a stock memorable.

1
The Basics
A micro-cap biopharmaceutical company · listed on NYSE American · headquartered in Florida · focused on immunology and antiviral research.
2
The Numbers
Annual revenues in the low single-digit millions — firmly in clinical-stage territory — with a market cap that has spent years well under $100 million.
3
The History
The company has been pursuing its core drug candidate for decades, originally exploring it as a broad-spectrum antiviral before pivoting toward cancer immunotherapy.
4
The Secret
Its lead compound is a double-stranded RNA molecule — a type of synthetic immune-system activator — studied across chronic fatigue syndrome, HIV, and solid tumors.
5
The Lore
The drug has been in clinical development so long it has become something of a cult obsession among patient advocates, particularly those with myalgic encephalomyelitis / chronic fatigue syndrome.
6
The Giveaway
Its flagship compound is called Ampligen (rintatolimod) — one of the few drugs ever to receive an FDA complete response letter for chronic fatigue syndrome, keeping hope alive for a very devoted patient community.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$22.0K

Net Income

Q1 2026

$-3.0M

Free Cash Flow

Q1 2026

$-2.7M

ROIC

Q1 2026

-35.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-15.8% YoY

$170.0KFY 2024

FY21 $135.0KFY22 $141.0KFY23 $202.0KFY24 $170.0K

Net Income

+40.2% YoY

$-17.3MFY 2024

FY21 $-19.1MFY22 $-19.4MFY23 $-29.0MFY24 $-17.3M

Operating Income

+38.0% YoY

$-19.8MFY 2024

FY21 $-18.8MFY22 $-19.9MFY23 $-31.9MFY24 $-19.8M

EPS (Diluted)

-5053.3% YoY

$-30.89FY 2024

FY21 —FY22 $-0.40FY23 $-0.60FY24 $-30.89

Total Assets

-55.6% YoY

$8.6MFY 2024

FY21 $57.7MFY22 $40.5MFY23 $19.4MFY24 $8.6M

Total Debt

$5.1MFY 2024

FY21 —FY22 —FY23 —FY24 $5.1M

Op. Cash Flow

+30.0% YoY

$-14.9MFY 2024

FY21 $-14.0MFY22 $-16.1MFY23 $-21.3MFY24 $-14.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$170.0K -15.8%	$202.0K +43.3%	$141.0K +4.4%	$135.0K -17.2%	$163.0K +16.4%	$140.0K
Net Income	$-17.3M +40.2%	$-29.0M -48.9%	$-19.4M -1.7%	$-19.1M -32.8%	$-14.4M -53.1%	$-9.4M
Operating Income	$-19.8M +38.0%	$-31.9M -60.2%	$-19.9M -5.8%	$-18.8M -24.3%	$-15.2M -21.8%	$-12.4M
EPS (Diluted)	$-30.89 -5053.3%	$-0.60 -50.0%	$-0.40	—	—	—
Total Assets	$8.6M -55.6%	$19.4M -52.1%	$40.5M -29.8%	$57.7M -10.7%	$64.6M +219.4%	$20.2M
Total Debt	$5.1M	—	—	—	$2.3M -7.7%	$2.5M
Operating Cash Flow	$-14.9M +30.0%	$-21.3M -32.0%	$-16.1M -15.3%	$-14.0M -34.7%	$-10.4M -14.3%	$-9.1M

Get alerted when AIM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AIM ImmunoTech Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AIM

GEODE CAPITAL MANAGEMENT, LLC
$17.5K29,918 sh
XTX Topco Ltd
$12.0K20,590 sh
JANE STREET GROUP, LLC
$11.7K20,047 sh
VANGUARD FIDUCIARY TRUST CO
$10.2K17,519 sh
Tower Research Capital LLC (TRC)
$2.7K4,668 sh
MORGAN STANLEY
$505.00864 sh
Community Bank, N.A.
$76.00132 sh
Virtu Financial LLC
$30.0050,895 sh
HARBOUR INVESTMENTS, INC.
$19.0032 sh
CREATIVE FINANCIAL DESIGNS INC /ADV
$18.0030 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$17.5K	29,918
XTX Topco Ltd	$12.0K	20,590
JANE STREET GROUP, LLC	$11.7K	20,047
VANGUARD FIDUCIARY TRUST CO	$10.2K	17,519
Tower Research Capital LLC (TRC)	$2.7K	4,668
MORGAN STANLEY	$505.00	864
Community Bank, N.A.	$76.00	132
Virtu Financial LLC	$30.00	50,895
HARBOUR INVESTMENTS, INC.	$19.00	32
CREATIVE FINANCIAL DESIGNS INC /ADV	$18.00	30

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AIM on your watchlist

Track score changes the day AIM ImmunoTech Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AIM a good stock to buy?

13F Pro's AI-powered analysis of AIM ImmunoTech Inc. (AIM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AIM are available on the AIM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AIM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AIM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AIM ImmunoTech Inc.'s investment landscape.